This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Beats on Q2 Earnings and Revenues, Revises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal second quarter.
Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Revenue growth across the BSI and BEST businesses drove Bruker's (BRKR) first-quarter 2022 revenues.
Tandem Diabetes (TNDM) Q1 Earnings Lag Estimates, Sales View Up
by Zacks Equity Research
Robust pump shipments and growth in the installed customer base are driving Tandem Diabetes' (TNDM) first-quarter top line.
Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
by Zacks Equity Research
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.
NuVasive (NUVA) Q1 Earnings Beat Estimates, 2022 View Up
by Zacks Equity Research
Robust sales performance across all U.S. product lines drove NuVasive's (NUVA) Q1 top line.
Charles River (CRL) Q1 Earnings Top, Gross Margin Falls
by Zacks Equity Research
Charles River (CRL) Q1 results highlight 9.8% organic revenue growth, driven by strength across all three segments.
CVS Health (CVS) Q1 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
CVS Health (CVS) reports better-than-expected results for Q1, with robust segmental performance driving the top line.
Masimo's (MASI) Q1 Earnings Surpass Estimates, FY22 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments drive its Q1 sales.
Cerner (CERN) Q1 Earnings in Line, Revenues Lag Estimates
by Zacks Equity Research
Cerner's (CERN) first-quarter results benefit from gains across four of its business units.
PerkinElmer (PKI) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results benefit from a solid performance at Discover & Analytics Solutions business.
IDEXX (IDXX) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Strong sales at the CAG and Water businesses drove IDEXX's (IDXX) first-quarter 2022 revenues.
AmerisourceBergen (ABC) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results benefit from segmental growth.
Zimmer Biomet (ZBH) Q1 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions recorded year-over-year sales growth at CER.
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Henry Schein (HSIC) Q1 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Robust performances by all three operating segments drove Henry Schein's (HSIC) first-quarter 2022 revenues.
Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust sales performance across Omnicell's (OMCL) operating segments has contributed to the first-quarter top line.
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health's (SYNH) revenues increased year over year in the first quarter, led by strong performances by the Clinical Solutions and Commercial Solutions arms.
5 Top Stocks Likely to Beat Earnings Estimates
by Sanghamitra Saha
These top-ranked stocks (ALKS, DRVN, TSLA, CIB, TFII) are likely to beat on bottom line in their next releases.
Surmodics (SRDX) Beats on Q2 Earnings, Revises FY22 View
by Zacks Equity Research
Despite solid IVD revenues, Surmodics (SRDX) reports a soft Q2 overall top line.
Accuray (ARAY) Q3 Earnings Beat Estimates, Revenues Lag
by Zacks Equity Research
Despite strong product demand, Accuray (ARAY) reports an overall soft Q3 performance.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings reflect strong performance across its segments.
DexCom (DXCM) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Despite a decline in bottom line, DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth and solid new customer additions.
Alkermes (ALKS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Alkermes (ALKS) rides high on both earnings and sales beating estimates in the first quarter of 2022.
Alkermes (ALKS) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 1,100% and 6.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?